Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Valeant’s Plaque Psoriasis Drug Gains FDA Approval

XTALKS VITALS NEWS

FDA

The drug is a monoclonal antibody designed to bind to the IL-17 receptor to inhibit the inflammatory response that contributes to the symptoms of plaque psoriasis.

Share this!

February 21, 2017 | by Sarah Hand, M.Sc.

The US Food and Drug Administration (FDA) has approved Valeant’s injectable plaque psoriasis drug, Siliq (brodalumab). The drug is a monoclonal antibody designed to bind to the IL-17 receptor to inhibit the inflammatory response that contributes to the symptoms of plaque psoriasis.

Siliq has been approved to treat adult patients with moderate-to-severe plaque psoriasis. Patients who have been previously unresponsive to systemic therapy or phototherapy are candidates for treatment with Siliq.

“Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today's approval provides patients with another treatment option for their psoriasis,” said Dr. Julie Beitz, director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research. “Patients and their healthcare providers should discuss the benefits and risks of Siliq before considering treatment.”

Psoriasis is an autoimmune disorder characterized by flaky, red patches on the skin. Approximately 7.5 million Americans suffer from the skin condition, with 80 to 90 percent of these patients being diagnosed with plaque psoriasis.



“We believe Siliq fulfills a significant unmet medical need, and I am proud of our team's success in developing and bringing to market this treatment for patients with moderate-to-severe plaque psoriasis,” said Joseph C. Papa, Chairman and CEO of Valeant. “We are pleased that Siliq will soon be available to help treat the suffering of adults who live with this debilitating, incurable condition, and further our mission to improve people's lives with our healthcare products.”

Three placebo-controlled clinical trials with a combined enrollment of 4,373 patients with plaque psoriasis, were used to assess the safety and efficacy of Siliq. Compared to the placebo, patients treated with Siliq showed clear, or almost clear skin, as assessed by a scoring matrix of psoriasis severity.

“Siliq is the only product that has demonstrated 100% improvement in the psoriasis area and severity index (PASI 100) during clinical trials as a primary endpoint,” said Dr. Lawrence J. Green, associate clinical professor of Dermatology at George Washington University School of Medicine in Washington, D.C. “As the first IL-17 receptor A blocker that helps stop the proinflammatory cascade that leads to psoriasis, resulting in the normalization of skin inflammation, this is a significant achievement for the many patients who suffer with moderate-to-severe plaque psoriasis. Siliq will be a welcomed addition to my treatment armamentarium.”

Due to the observed risk of suicidal ideation or behavior in some patients taking Siliq, the drug carries an FDA black box warning. Because of this risk, the drug will only be available under a Risk Evaluation and Mitigation Strategy (REMS), which requires prescribers to be certified to counsel patients about the mental health risks.


Keywords: Psoriasis, FDA, Black Box Warning


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News


Smartphone App Created Using Apple’s ResearchKit Used to Conduct Asthma Clinical Studies

March 22, 2017 - Researchers at the Icahn School of Medicine at Mount Sinai have conducted a large-scale, observational study of asthma patients using the Apple ResearchKit framework and the Asthma Health app on patients’ iPhones.

Featured In: Clinical Trials News


IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.